Van that OPKO is so shorted for a reason the head guy at opko has been investigated and if he would leave the stk would go up.
OPKO Health: A $10 Stock On Sale Now For Only $4
Dec. 31, 2020 2:55 PM ETOPKO Health, Inc. (OPK)
Since the battle against COVID-19 started in the U.S. back in March, OPKO has been on the front lines of the heroic efforts to contain the virus as it ravages the country. On one front, OPKO's pharmaceutical business has been conducting a trial for their prescription vitamin D treatment Rayaldee as a therapeutic to combat the effects of COVID-19
Playing a more featured role in this Covid war is OPKO's diagnostics segment, BioReference Laboratories ("BRL"), which has become the third-largest provider of laboratory testing services in the country. BRL is famously known for the incredible work they've done supporting the NBA in the Orlando bubble that allowed the league to carry out a successful season and led to a contract renewal by the NBA for the 2021 campaign. OPKO is also providing COVID testing services for the NFL.
Q4 2020 Earnings Projection
OPKO's expects revenue for Q4, 2020 to $400 - 430 million, including services revenue between $370 - 400 million, product revenues between $25 - 30 million, and other revenue between $6 - 8 million. We expect costs and expenses to increase to between $380 - 400 million resulting in an operating profit of $20 to $30 million between the revenue and expense assumptions. The increase in costs and expenses are strictly attributable to the cost of sales as we remain committed to controlling all our other operating expense line items.
Leveraging the high-end revenue and cost estimates
The ongoing challenge for OPKO investors has been both the very large float of over 670 million shares outstanding and the checkered history that has resulted in sustained and ruthless shorting campaigns. Shorting challenges presented by the "convertible bondholders", some seasoned observers believe that those noteholders have actually become "long" OPKO Health based on improving performance.
The other key risk is whether OPKO can quickly and efficiently increase testing capacity to meet the obvious and growing demand as Covid-19 surges. OPKO hasn't done as effective a job on that as many investors would like.
We anticipate performing between 3.2 to 3.8 million COVID-19 PCR antigen and antibody tests
Based on the material OPKO presented at the most recent investor conference, they have increased their testing capacity, up from the previous 40-50k in Q3 to 100k PCR tests and 400k antibody tests per day in November. //They have also been acting on their stated strategic objective build on the goodwill generated with institutions during the pandemic to create ongoing diagnostic relationships. -->The announcement in May of BRL and Westchester Medical Center Health Network entering into a new "Strategic Laboratory Collaboration" to deliver operational and diagnostic services. -->In addition, OPKO has been partnering with New York, New Jersey, and Florida, multiple cities, municipalities and hospital systems and operating more PCR collection sites than any other commercial laboratory in the country. <---
This is key so what we have is cost of sales going through the roof as OPKo tris to secure relationships that will bear fruit in a continuing testing environment.///
Now just today there was news that the PCR test is not so reliable which we al know... if you have symptoms it's a good test but if you do not have symptoms it misses a lot. I had an investment in FLDM which sort of merged these worlds they had PCR tests run on some DNA platform which bettered the result and ORASURE is trying some version of this as well...
A lot of cross winds... But a name to watch--- Opko.
PS: tens of millions of OPK shares bought over the last few quarters by blue-chip investment firms like Blackrock and Goldman Sachs....
OPKO Health: A $10 Stock On Sale Now For Only $4
Dec. 31, 2020 2:55 PM ETOPKO Health, Inc. (OPK)
Since the battle against COVID-19 started in the U.S. back in March, OPKO has been on the front lines of the heroic efforts to contain the virus as it ravages the country. On one front, OPKO's pharmaceutical business has been conducting a trial for their prescription vitamin D treatment Rayaldee as a therapeutic to combat the effects of COVID-19
Playing a more featured role in this Covid war is OPKO's diagnostics segment, BioReference Laboratories ("BRL"), which has become the third-largest provider of laboratory testing services in the country. BRL is famously known for the incredible work they've done supporting the NBA in the Orlando bubble that allowed the league to carry out a successful season and led to a contract renewal by the NBA for the 2021 campaign. OPKO is also providing COVID testing services for the NFL.
Q4 2020 Earnings Projection
OPKO's expects revenue for Q4, 2020 to $400 - 430 million, including services revenue between $370 - 400 million, product revenues between $25 - 30 million, and other revenue between $6 - 8 million. We expect costs and expenses to increase to between $380 - 400 million resulting in an operating profit of $20 to $30 million between the revenue and expense assumptions. The increase in costs and expenses are strictly attributable to the cost of sales as we remain committed to controlling all our other operating expense line items.
Leveraging the high-end revenue and cost estimates
The ongoing challenge for OPKO investors has been both the very large float of over 670 million shares outstanding and the checkered history that has resulted in sustained and ruthless shorting campaigns. Shorting challenges presented by the "convertible bondholders", some seasoned observers believe that those noteholders have actually become "long" OPKO Health based on improving performance.
The other key risk is whether OPKO can quickly and efficiently increase testing capacity to meet the obvious and growing demand as Covid-19 surges. OPKO hasn't done as effective a job on that as many investors would like.
We anticipate performing between 3.2 to 3.8 million COVID-19 PCR antigen and antibody tests
Based on the material OPKO presented at the most recent investor conference, they have increased their testing capacity, up from the previous 40-50k in Q3 to 100k PCR tests and 400k antibody tests per day in November. //They have also been acting on their stated strategic objective build on the goodwill generated with institutions during the pandemic to create ongoing diagnostic relationships. -->The announcement in May of BRL and Westchester Medical Center Health Network entering into a new "Strategic Laboratory Collaboration" to deliver operational and diagnostic services. -->In addition, OPKO has been partnering with New York, New Jersey, and Florida, multiple cities, municipalities and hospital systems and operating more PCR collection sites than any other commercial laboratory in the country. <---
This is key so what we have is cost of sales going through the roof as OPKo tris to secure relationships that will bear fruit in a continuing testing environment.///
Now just today there was news that the PCR test is not so reliable which we al know... if you have symptoms it's a good test but if you do not have symptoms it misses a lot. I had an investment in FLDM which sort of merged these worlds they had PCR tests run on some DNA platform which bettered the result and ORASURE is trying some version of this as well...
A lot of cross winds... But a name to watch--- Opko.
PS: tens of millions of OPK shares bought over the last few quarters by blue-chip investment firms like Blackrock and Goldman Sachs....
